BeOne Medicines files STAR interim report; total R&D rose to $1.15 billion
BeOne Medicines filed its 2026 interim report for the six months ended June 30, 2026, with Shanghai's STAR Market and furnished an R&D expense breakdown under Item 2.02. The filing gives total R&D expenses of $1.15 billion for the period versus $1.01 billion a year earlier, but it does not report revenue, net income or EPS, and the full report is in Chinese only.
Key points
- Total R&D expenses were $1.15 billion for the six months ended June 30, 2026, versus $1.01 billion for the same period in 2025.
- Internal R&D expenses were $718.4 million, up from $606.5 million; external R&D expenses were $435.1 million, up from $400.3 million.
- BRUKINSA R&D expenses fell to $42.7 million from $63.0 million, and BEQALZI R&D expenses fell to $74.0 million from $94.0 million.
- The STAR Interim Report is available only in Chinese on the Shanghai Stock Exchange website and is not filed with the SEC.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.